2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 493

Efficacy and Safety of Tofacitinib Following Inadequate Response to Nonbiologic DMARD or Biologic DMARD
Abstract Number: 539

Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Abstract Number: 497

Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs
Abstract Number: 2821

Efficacy and Safety/Tolerability of Mavrilimumab, a Human GM-CSFRÃ¡ Monoclonal Antibody in Patients with Rheumatoid Arthritis
Abstract Number: 2474

Efficacy and Tolerability of Subcutaneous Methotrexate for Inflammatory Arthritis: A Retrospective Observational Cohort Study
Abstract Number: 2528

Efficacy Meta-Analysis of Randomized Controlled Trials (RCTs) of Biologics in Methotrexate-Naive Patients with Early Rheumatoid Arthritis
Abstract Number: 2354

Efficacy of a Novel Orally Bioavailable JAK1 Selective Compound in a Preclinical Rat Collagen-Induced Arthritis Model
Abstract Number: 1240

Efficacy of Anakinra in Refractory Adult-Onset Still´s Disease: Multicenter Study of 41 Patients
Abstract Number: 879

Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Rapidly Progressive Systemic Sclerosis: Prolonged Remission of Disease Activity in a Long-Term Follow up
Abstract Number: 2419

Efficacy of Biologic Medications in Active Rheumatoid Arthritis: A Systematic Review
Abstract Number: 1527

Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: An Indirect Comparison
Abstract Number: 2526

Efficacy of Biological Therapies in Rheumatoid Arthritis: Graphical Modeling of DAS28 Components’ Evolution over Time
Abstract Number: 2297

Efficacy of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) using JADAS Criteria – an Analysis of 12-Week Pooled Data
Abstract Number: 1251

Efficacy of Certolizumab in Patients with Refractory Uveitis to Other Biologic Therapy. Study of 7 Cases
Abstract Number: 2371

Efficacy of First Line Biological Monotherapy in RA: Data from the Czech Registry Attra

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].